Cargando…
Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST)
OBJECTIVE: The aim was to report results from PERSIST, a real-life, observational, prospective cohort study of CT-P13, an infliximab (IFX) biosimilar, for treatment of patients with RA, AS or PsA who were biologic naïve or switched from an IFX reference product (IFX-RP; Remicade). METHODS: Adult pat...
Autores principales: | Taylor, Peter C, Christensen, Robin, Moosavi, Shahrzad, Selema, Pamela, Guilatco, Ruffy, Fowler, Heather, Mueller, Markus, Liau, Katherine F, Haraoui, Boulos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346696/ https://www.ncbi.nlm.nih.gov/pubmed/34377890 http://dx.doi.org/10.1093/rap/rkab026 |
Ejemplares similares
-
Three-year safety observation of subcutaneous administration of epoetin-zeta in patients with chronic renal anemia: Results from PASCO II study
por: Patsialas, Stavros, et al.
Publicado: (2023) -
Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years
por: Pope, Janet E., et al.
Publicado: (2019) -
Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
por: Choquette, Denis, et al.
Publicado: (2019) -
PERSISTENCE OF STREPTOCOCCAL GROUP A ANTIBODY IN PATIENTS WITH RHEUMATIC VALVULAR DISEASE
por: Dudding, Burton A., et al.
Publicado: (1968) -
Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: a systematic literature review
por: Luttropp, Karin, et al.
Publicado: (2019)